Funobactam

Tier C — Watch / trade

Funobactam

Sinovent Pty Ltd

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：Beta Lactamase

Indications (approved)：Community-acquired bacterial pneumonia, Pyelonephritis, Bacterial pneumonia, Urinary tract infection, Hospital-acquired pneumonia, Gram-negative bacterial infection, Bacterial infection

Regional status

Phase III

2022-10-29

Phase III

2022-10-29

China

Phase III

2023-03-31

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Funobactam?

Approved indications include: Community-acquired bacterial pneumonia, Pyelonephritis, Bacterial pneumonia, Urinary tract infection, Hospital-acquired pneumonia, Gram-negative bacterial infection, Bacterial infection.

When does the Funobactam patent expire?

No public expiry year is available for Funobactam yet; this page updates once verified.

How do I get a quote for Funobactam intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-03